Literature DB >> 34108052

Long non-coding RNA KCNQ1OT1 promotes cell viability and migration as well as inhibiting degradation of CHON-001 cells by regulating miR-126-5p/TRPS1 axis.

Binfeng Wang1, Xiangwei Liu2.   

Abstract

BACKGROUND: Osteoarthritis (OA) is defined as a degenerative disease. Pivotal roles of long non-coding RNA (lncRNAs) in OA are widely elucidated. Herein, we intend to explore the function and molecular mechanism of lncRNA KCNQ1OT1 in CHON-001 cells.
METHODS: Relative expression of KCNQ1OT1, miR-126-5p and TRPS1 was determined by quantitative real-time polymerase chain reaction (qRT-PCR). Cell viability was examined by MTT assay. The migratory ability of chondrocytes was assessed by transwell assay. Western blot was used to determine relative protein expression of collagen II, MMP13 and TRPS1. Dual-luciferase reporter (DLR) assay was applied to test the target of lncRNA KCNQ1OT1 or miR-126-5p.
RESULTS: Relative expression of KCNQ1OT1 and TRPS1 was reduced, whereas miR-126-5p was augmented in cartilage tissues of post-traumatic OA patients compared to those of subjects without post-traumatic OA. Increased KCNQ1OT1 or decreased miR-126-5p enhanced cell viability and migration, and repressed extracellular matrix (ECM) degradation in CHON-001 cells. MiR-126-5p was the downstream target of KCNQ1OT1, and it could directly target TRPS1. There was an inverse correlation between KCNQ1OT1 and miR-126-5p or between miR-126-5p and TRPS1. Meantime, there was a positive correlation between KCNQ1OT1 and TRPS1. The promoting impacts of KCNQ1OT1 on cell viability and migration as well as the suppressive impact of KCNQ1OT1 on ECM degradation were partially abolished by miR-126-5p overexpression or TRPS1 knockdown in CHON-001 cells.
CONCLUSIONS: Overexpression of KCNQ1OT1 attenuates the development of OA by sponging miR-126-5p to target TRPS1. Our findings may provide a possible therapeutic strategy for human OA in clinic.

Entities:  

Keywords:  KCNQ1 overlapping transcript 1; Post-traumatic osteoarthritis; Tricho-rhino-phalangeal syndrome type I; miR-126-5p

Mesh:

Substances:

Year:  2021        PMID: 34108052     DOI: 10.1186/s42358-021-00187-3

Source DB:  PubMed          Journal:  Adv Rheumatol        ISSN: 2523-3106


  36 in total

1.  American Academy of Orthopaedic Surgeons clinical practice guideline on the treatment of osteoarthritis (OA) of the knee.

Authors:  John Richmond; David Hunter; James Irrgang; Morgan H Jones; Lynn Snyder-Mackler; Daniel Van Durme; Cheryl Rubin; Elizabeth G Matzkin; Robert G Marx; Bruce A Levy; William C Watters; Michael J Goldberg; Michael Keith; Robert H Haralson; Charles M Turkelson; Janet L Wies; Sara Anderson; Kevin Boyer; Patrick Sluka; Justin St Andre; Richard McGowan
Journal:  J Bone Joint Surg Am       Date:  2010-04       Impact factor: 5.284

2.  LncRNA TUG1 promotes osteoarthritis-induced degradation of chondrocyte extracellular matrix via miR-195/MMP-13 axis.

Authors:  L-P Tang; J-B Ding; Z-H Liu; G-J Zhou
Journal:  Eur Rev Med Pharmacol Sci       Date:  2018-12       Impact factor: 3.507

Review 3.  Kcnq1ot1: a chromatin regulatory RNA.

Authors:  Chandrasekhar Kanduri
Journal:  Semin Cell Dev Biol       Date:  2011-02-21       Impact factor: 7.727

Review 4.  Protective effects of the pericellular matrix of chondrocyte on articular cartilage against the development of osteoarthritis.

Authors:  Chenlu Liu; Beiyu Wang; Li Xiao; Yefu Li; Lin Xu; Zhihe Zhao; Lin Zhang
Journal:  Histol Histopathol       Date:  2018-01-23       Impact factor: 2.303

Review 5.  Current Treatment Options for Osteoarthritis.

Authors:  Walter Hermann; Sevdalina Lambova; Ulf Muller-Ladner
Journal:  Curr Rheumatol Rev       Date:  2018

Review 6.  Epidemiology of osteoarthritis and associated comorbidities.

Authors:  Pradeep Suri; David C Morgenroth; David J Hunter
Journal:  PM R       Date:  2012-05       Impact factor: 2.298

7.  Randomized controlled trial on low level laser therapy (LLLT) in the treatment of osteoarthritis (OA) of the hand.

Authors:  Lucie Brosseau; George Wells; Serge Marchand; Isabelle Gaboury; Barbara Stokes; Michelle Morin; Lynn Casimiro; Katharine Yonge; Peter Tugwell
Journal:  Lasers Surg Med       Date:  2005-03       Impact factor: 4.025

Review 8.  Current pharmacological treatment of osteoarthritis.

Authors:  F A Wollheim
Journal:  Drugs       Date:  1996       Impact factor: 9.546

Review 9.  Knockdown of lncRNA MFI2-AS1 inhibits lipopolysaccharide-induced osteoarthritis progression by miR-130a-3p/TCF4.

Authors:  Xiaofei Luo; Jinliang Wang; Xuan Wei; Shaohua Wang; Aiguo Wang
Journal:  Life Sci       Date:  2019-10-31       Impact factor: 5.037

Review 10.  LncRNA MALAT1 promotes osteoarthritis by modulating miR-150-5p/AKT3 axis.

Authors:  Ying Zhang; Fuyou Wang; Guangxing Chen; Rui He; Liu Yang
Journal:  Cell Biosci       Date:  2019-07-01       Impact factor: 7.133

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.